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Clathrins are cytoplasmic proteins that play essential roles
in endocytosis and other membrane traffic pathways. Upon
recruitment to intracellular membranes, the canonical clathrin
triskelion assembles into a polyhedral protein coat that facili-
tates vesicle formation and captures cargo molecules for trans-
port. The triskelion is formed by trimerization of three clathrin
heavy-chain subunits. Most vertebrates have two isoforms of
clathrin heavy chains, CHC17 and CHC22, generating two
clathrins with distinct cellular functions. CHC17 forms vesicles
at the plasmamembrane for receptor-mediated endocytosis and
at the trans-Golgi network for organelle biogenesis. CHC22
plays a key role in intracellular targeting of the insulin-regulated
glucose transporter 4 (GLUT4), accumulates at the site of
GLUT4 sequestration during insulin resistance, and has also
been implicated in neuronal development. Here, we demon-
strate that CHC22 and CHC17 share morphological features,
in that CHC22 forms a triskelion and latticed vesicle coats.
However, cellular CHC22-coated vesicles were distinct from
those formed by CHC17. The CHC22 coat was more stable to
pH change and was not removed by the enzyme complex that
disassembles the CHC17 coat. Moreover, the two clathrins
were differentially recruited to membranes by adaptors, and
CHC22 did not support vesicle formation or transferrin
endocytosis at the plasma membrane in the presence or
absence of CHC17. Our findings provide biochemical evi-
dence for separate regulation and distinct functional niches
for CHC17 and CHC22 in human cells. Furthermore, the
greater stability of the CHC22 coat relative to the CHC17 coat
may be relevant to its excessive accumulation with GLUT4
during insulin resistance.
Clathrin is a triskelion-shaped (three-legged) protein that is
recruited by adaptor molecules to cellular membranes where it
self-assembles into a latticed coat, driving membrane bud for-
mation. Simultaneously, clathrin organizes adaptor molecules,
capturing membrane-embedded cargo for sorting into result-
ing clathrin-coated vesicles (CCVs)4 (1, 2). Clathrin heavy-
chain (CHC) subunits form a triskelion by trimerization at their
C terminus. Most vertebrates (mice being a notable exception)
have two CHC isoforms, CHC17 and CHC22, generated by
genome duplication during vertebrate evolution (3). CHC17
triskelia mediate the canonical functions associated with clath-
rin, including receptor-mediated endocytosis and lysosome
biogenesis. Bound to the center of CHC17 triskelia are the
clathrin light-chain (CLC) subunits that influence assembly
and leg rigidity (1, 4, 5). CHC22, which does not naturally bind
CLCs, still shares 85% amino acid sequence identity with
CHC17 (6). Despite this high degree of homology, CHC22
plays different cellular roles than CHC17 clathrin. In humans,
CHC22 is expressed primarily inmuscle and fat (7) and appears
transiently during neuronal development (8) in contrast to the
ubiquitous and chronic expression of CHC17. In muscle and
fat, CHC22 is required for formation of the glucose transporter
4 (GLUT4) storage compartment (GSC), fromwhichGLUT4 is
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released to the cell surface in response to insulin signaling (7, 9).
Although mice have a similar insulin response leading to
GLUT4 translocation in muscle and fat, CHC22 clathrin par-
ticipation is a feature of human GSC formation that is absent
from murine models. Additionally, CHC22 accumulates at
over-loaded GLUT4 compartments that can form during insu-
lin-resistant type 2 diabetes (T2D), suggesting a potential role
for CHC22 in pathogenesis (7).
Here, we compare the biochemical, morphological, and
functional properties of CHC17 and CHC22 to understand
their ability to operate in separate biological niches and gain
insight into the properties of assembled CHC22 that might be
relevant to human insulin resistance. In this study, we have
produced the first images of purified CHC22 CCVs and triske-
lia, both resembling structures formed by CHC17 (10–12). We
demonstrate that CHC22 and CHC17 form segregated coated
vesicles and that regulation of theirmembrane recruitment and
disassembly, as well as uncoating, is distinct. Although a previ-
ous report suggested that CHC22 could functionally substitute
for CHC17 at the plasma membrane (13), we found this not to
be the case for either endocytic-coated vesicle formation or
transferrin uptake. Thus fundamental biochemical differences
underlie the non-redundant functions of the two clathrins.
These differences are relevant to CHC22 function in human
health and disease, and could account for some of the docu-
mented differences in human and murine glucose metabolism
noted from mouse models (14, 15).
Results
CHC22 forms coated vesicles that are distinct from those
formed by CHC17
Functional studies indicate that CHC22 and CHC17 operate
in separate membrane traffic pathways in formation of the
humanGLUT4 storage compartment (7), and the two isoforms
are separately immunoprecipitated from cell lysate (6). Our
previous immunofluorescence studies in human skeletal mus-
cle showed that CHC17 and CHC22 are typically found at sep-
arate locations in cells, with about 15% overlap (by Pearson’s
correlation) (7). This suggests that a small fraction of intracel-
lular membrane might be coated with mixtures of CHC17 and
CHC22. However, CHC22 was implicated as a component of
CHC17-coated vesicles by proteomics experiments, which
showed that CHC22 was depleted from CCV preparations fol-
lowing siRNA-mediated down-regulation of CHC17 (16). We
therefore sought to establish the degree to which CHC22 and
CHC17 form mixed lattices in cells.
To this end, we purified clathrin-coated vesicles from HeLa
cells using the same CCV purification protocol as in the cited
proteomics study (16, 17), and note that HeLa cells (atypical for
their tissue origin) express CHC22 at similar levels to human
myotubes (9).We found that a Tris/acetate/EDTA (TAE)-buff-
ered SDS-PAGE system described previously (18) separates
CHC22 and CHC17 by electrophoretic mobility (Fig. 1, A and
B) and this analysis revealed that both isoforms were present in
Figure 1. CHC22 forms a latticed coat on vesicles that are distinct from CHC17-coated vesicles. A, immunoblot of CCV purification from HeLa cell
homogenate (H) showing the supernatant (S) and pellet (P) fractions for each differential centrifugation step and the final CCV pellet (HS, high-speed; Ultra-C,
ultra-centrifugation; F/S, high-speed centrifugation in Ficoll/sucrose). Sampleswere analyzed by TAE SDS-PAGE to separate the twoCHC isoforms, whichwere
detectedwith amixture of anti-CHC17 (TD.1) and anti-CHC22 (SHL-KS) antibodies followed byHRP-conjugated secondary antibodies. B,HeLa cell lysateswere
separated by TAE SDS-PAGE, transferred to nitrocellulose, and analyzed by immunoblotting. Blot lanes were cut into strips and incubated separately with
anti-CHC17 (TD.1, lane 1), anti-CHC22 (SHL-KS, lane 2), or mixed TD.1 and SHL-KS (lane 3). Blotted strips were re-joined for imaging. Note that the antibody
mixture inAwas optimized to detect both CHC isoforms equally (“Experimental procedures”), whereas themixture in B represents the antibody dilutions used
in the individually blotted strips. C, CCV fraction from A was co-labeled with immunogold for CLC bound to CHC17 (CLC/CHC17, 10 nm particles, filled
arrowheads) and CHC22 (5 nm particles, open arrowheads) and stained with uranyl acetate. Individual vesicles labeled for CLC/CHC17 or CHC22 are shown.
Brightness of the images was adjusted to improve visibility of gold particles. D, larger image from co-labeling as in C showing vesicles labeled independently
for CLC/CHC17 and CHC22 in the same field, as for C. E, for CCVs labeledwith 1, 2, 3, or4 gold particles, the number labeled individually for each CHC isoform
or labeled for both isoforms is shown. For the total number of CCVs (n306) labeledwith twoormoregoldparticles (2), thepercentage labeled for bothCHC
isoforms (21 total), or only one isoform (285 total) is indicated. F,observednumbers of CCVs decoratedwith twogold particles (from E) that are labeled for both
isoforms or labeled individually compared with the expected labeling if coats comprise both isoforms (accounting for labeling efficiency and relative isoform
abundance, see “Experimental procedures”). Elevenobserveddual-labeledCCVswas significantly lower than the expected 89dual-labeledCCVs ifmixed coats
(2 test, **** p 0.0001, n 190 CCVs with two labels, df 1; “Experimental procedures”). For gels and blots, the migration positions of molecular mass
markers are indicated at the right in kilodaltons. Scale bars (C and D) 100 nm.
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the coated vesicle preparation (Fig. 1A), suggesting that CHC22
is found in structures of a similar size and density as CHC17
structures known to be CCVs.We then examined the CCVs by
immunoelectron microscopy using an anti-CLC antibody to
detect CHC17 and an isoform-specific anti-heavy-chain anti-
body to detect CHC22. Immunogold labeling with secondary
antibodies coupled to different-sized gold particles revealed
that CCVs were primarily labeled for only one CHC isoform
(Fig. 1, C and D). Quantification showed that 93.1% of CCVs
with two or more gold particles were labeled by antibodies rec-
ognizing either CHC22 or CHC17 but not both (Fig. 1E). Sta-
tistical analysis of CCVs labeledwith two gold particles demon-
strated that the number of CCVs co-labeled for both CHC17
and CHC22 was significantly below the number that would
be expected to co-label for both clathrins if mixed coats are
formed, taking into account the efficiency of antibody labeling
and the relative abundance (9) of the two clathrin heavy chains
in HeLa cells (Fig. 1F; “Experimental procedures”). Negatively
stained images showed that vesicles labeled only for CHC22
were coatedwith lattices visually similar to CHC17 lattices (Fig.
1, C and D). This analysis by electron microscopy reveals that
when purified from cells, CHC22 CCVs are predominantly dis-
tinct from those formed by CHC17 (Fig. 1), although their lat-
tices share morphology.
CHC22 and CHC17 coats have distinct biochemical
dissociation properties and both clathrins are triskelia
The clathrin coat was first described for its lattice (clathrate)
structure (19), and later CHC17 clathrin was shown to be a
triskelion (10–12). We previously showed by size-exclusion
chromatography that the recombinantly expressed C-terminal
third of CHC22 (Hub fragment, residues 1074–1640) forms a
trimer (6). However, due to low solubility (different from the
CHC17 Hub), it was not possible to obtain sufficient CHC22
Hub protein to visualize this fragment.Without a human tissue
source for purifying CHC22, we addressed whether we could
purify CHC22 following over-expression in tissue culture and
sought to take advantage of an existing HeLa cell transfectant
(HeLa-CHC22x9-TO) that can over-express CHC22x9
under the control of a Tet-On promoter (6). CHC22x9 pro-
tein lacks 60 amino acids (457–507 encoded by Exon 9) com-
prising the CHCR0 region between the distal leg and the
N-terminal domain, so that CHC22x9 is virtually full-
length (1580 of 1640 residues) with intact trimerization,
proximal, and distal leg and terminal domains. Doxycycline
treatment of HeLa-CHC22x9-TO caused CHC22x9 to be
the dominant clathrin in these cells (Fig. 2,A and B).We then
addressed whether CHC22 and CHC17 can be differentially
dissociated fromHeLa CCVs. It was previously observed that
high pH combined with low salt concentrations efficiently
strips CHC17 from membranes (20), so we tested the effects
of pH change in low salt on releasing CHC22 from CCVs
purified from untransfected HeLa cells. Sequential exposure
of mixed purified CCVs to increasing pH removed CHC17
without substantially dissociating CHC22 from their respec-
tive CCVs. Only 13% of CHC22 was solubilized at pH 8.5,
whereas 95% of CHC17 was released from the CCV mixture
(Fig. 2, C and D). From the pellet of CCVs exposed to pH 8.5,
we were able to solubilize CHC22 by exposure to 0.5 M Tris
Figure 2. The CHC22 clathrin coat is resistant to pH-dependent stripping frommembranes and CHC22x9 is a triskelion. A and B,HeLa-CHC22x9-TO
cells were incubated with doxycycline for 24 h at the concentrations indicated and cell lysates were prepared. Representative immunoblot (A) and quantifi-
cation (B, average S.E.) of signals for CHC17 and CHC22x9 relative to no doxycycline treatment, normalized to GAPDH for each sample (n 5). C, purified
CCVs from untransfected HeLa cells were exposed to increasing pH by sequential suspension in buffer with the indicated pH and subsequent centrifugation
(see flow scheme below). Representative immunoblot (above) of CHC isoforms released from CCVs in the indicated supernatants (S) designated for each pH
treatment;P1, final CCVpellet after sequential treatmentwith increasingpH; S-HT, supernatant released following treatment of P1withhighTris (0.5M);P2, CCV
pellet after high Tris treatment. D, quantification of the cumulative percent released after increasing pH treatment, as in C (n 3). E, immunoblot analysis of
CHCs purified by differential stripping of CCVs isolated from untransfected HeLa (CHC17) and doxycycline-treated HeLa-CHC22x9-TO cells. F, purified CHC
isoforms from E visualized by deep-etch electron microscopy. Representative electron micrographs of CHC17 (upper panels) and CHC22x9 (lower panels).
Brightness and contrast of the images were adjusted to improve visibility of the triskelia. Scale bar 50 nm. For all blots, themigration positions of molecular
mass markers are indicated at the right in kilodaltons and the specificity of the antibody used for blotting is shown at the left.
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buffer, another method used in standard protocols for puri-
fying CHC17 (21) (Fig. 2C).
To obtain purified CHC22x9, CCVs were isolated from
HeLa-CHC22x9-TO cells treated with doxycycline, then
exposed to increasing pH to remove CHC17, followed by Tris
stripping the final pellet to release CHC22x9. To obtain puri-
fied CHC17 for comparison, CCVswere purified fromuntrans-
fected HeLa cells (with a natural 10-fold excess of CHC17 over
CHC22), then exposed to pH 7.0, releasing CHC17 and leaving
CHC22 behind on pelleted membranes. Immunoblotting
with isoform-specific antibodies confirmed the purity of the
CHC22x9 and CHC17 obtained by these methods (Fig. 2E).
Analysis of the separated purified clathrin isoforms by deep-
etch electron microscopy showed that CHC22x9 has the
same triskelion configuration and approximate dimensions
as CHC17 (Fig. 2F), providing morphological evidence that
CHC22 is a triskelion.
Differential enzymatic uncoating of CHC22 and CHC17
The CHC17 triskelia cycle from the cytosol to nascent CCVs
at the plasma membrane or other organelles, and are returned
back to the cytosol by uncoating fully closed CCVs (1). Uncoat-
ing ismediated by anATPase complex consisting of the 70-kDa
heat-shock cognate protein (Hsc70) and auxilin, and requires
ATP hydrolysis (22, 23). Notably, CHC22 lacks the 5-residue
recognition site (QLMLT) for Hsc70 binding to CHC17 (24)
(Fig. 3A). Our previous work showed that, at steady state, most
cellular CHC22 is associatedwithmembranes, whereas CHC17
is about half-cytosolic at any one time (6), suggesting that
CHC22 disassembly dynamics are different from those of
CHC17. Furthermore, the in vitro conditions necessary to dis-
sociate CHC22 from CCVs for purification suggested differ-
ences in properties of CHC22 lattices compared with CHC17
lattices. We therefore addressed whether CHC22 CCVs are
uncoated by the same cellular mechanism that operates for
CHC17 coat disassembly. CCVs purified from HeLa cells were
incubated with recombinant uncoating complex (UC, Hsc70
plus a functional fragment of auxilin) with and without ATP.
After centrifugation, CHCs released to the supernatant or
remaining in the pellet were assessed by immunoblotting with
isoform-specific antibodies (Fig. 3B). The UC plus ATP effec-
tively removedmore than 50% of the CHC17 fromCCVs under
these conditions, but only 16%ofCHC22was released (Fig. 3C).
These data show that under conditions where CHC17 coats are
efficiently removed, theHsc70–auxilin complex is significantly
less efficient in uncoating CHC22 assemblies, consistent with
loss of Hsc70 efficacy when the QLMLT sequence is deleted
fromCHC17 (24). These findings indicate that CHC22 uncoat-
ing proceeds differently from CHC17 uncoating. Cellular
dissociation of CHC22 coats may be performed by different
proteins or under different conditions than cellular CHC17
disassembly.
Differential membrane recruitment of CHC22 and CHC17
Clathrin recruitment tomembranes is driven by adaptor pro-
teins that recognize phospholipids at specific intracellular loca-
Figure 3. CCVuncoatingandmembrane recruitmentdiffer for CHC17andCHC22.A, sequence alignment of theC-terminal portions of humanCHC17 and
CHC22. Identical amino acids aremarked in black. The Hsc70 recognition site at the C-terminal end of CHC17 (24) is boxed in red, showing the difference from
CHC22.B,CCVs fromHeLa cellswere incubatedwithout (control) orwith theUC (Hsc70 and cofactor auxilin) plus orminusATP. Uncoated clathrin triskeliawere
separated from residual CCVs by centrifugation. CHC17 or CHC22 were detected in resulting supernatants (S) and pellets (P) by separately immunoblotting
each sample with isoform-specific antibodies. C, quantification of uncoating efficiency (release of CHCs into supernatant, S/(SP) signals) from n 4 experi-
ments as in B. *, p 0.05 by Student’s t test, CHC17 versus CHC22. D, representative immunoblot showing CHC22, CHC17, AP-1, and GGA2 in cytosolic (C) or
membrane (M) fractions from HeLa cells stably expressing wild-type CD8 (CD8-WT) or chimeric CD8 with the intracellular domain of CI-MPR (CD8-CIMPR). E,
quantification of n  4–5 experiments as in C, expressed as membrane fraction signal divided by total signal, M/(C  M). **, p  0.01 by Student’s t test,
CD8-CIMPR versus CD8-WT. For all blots, the migration positions of molecular mass markers are indicated at the right in kilodaltons and the specificity of the
detecting antibodies is indicated at the left.
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tions and selectively interact with cargo (25). Immunoisolation
of CHC22 fromHeLa cells and human skeletalmuscle in earlier
studies showed co-purification of the adaptors AP1, AP3, and
GGA2 (Golgi-associated,  adaptin ear-containing, adenosine
diphosphate ribosylation factor–binding protein 2), but not the
plasmamembrane-associated adaptor AP2 (6, 7). Although the
adaptors bound to CHC22 also bind to CHC17, immunoisola-
tion showed more GGA2 co-isolated with CHC22 than with
CHC17 relative to the other adaptors (7), suggesting a possible
mechanism for their differential recruitment. To address CHC
interactions with GGA2, we examined whether forced mem-
brane association of GGA2 could attract CHC22 and/or
CHC17 tomembranes. It has been shown thatmembrane asso-
ciation of GGA2 dramatically increases in HeLa cells stably
expressing a chimeric CD8 protein with the cytoplasmic tail of
CIMPR (CD8-CIMPR) (26). In these cells, we assessed the pro-
portion of adaptors and clathrin that were membrane associ-
ated by immunoblotting the membrane and cytosol fractions
(Fig. 3, D and E). Compared with cells expressing CD8 without
the cytoplasmic domain of CIMPR (CD8-WT), the fractions of
GGA2 and CHC22 associated with membranes were signifi-
cantly increased in theCD8-CIMPRcells. Themembrane local-
ization of CHC17 appeared slightly increased in the CD8-
CIMPR cells, but this was not statistically significant (Fig. 3E).
Thus, increased membrane association of GGA2 correlates
with greater recruitment of CHC22 than CHC17, supporting
the biochemical evidence that preferential adaptor binding
properties contribute to differential localization and functions
of CHC22 and CHC17.
CHC22 does not substitute for CHC17 in endocytosis
Our previous work localized CHC22 function to internal
membrane traffic and showed by fluorescence microscopy that
down-regulation of CHC22 did not affect receptor-mediated
endocytosis of fluorescent transferrin (Tf) or epidermal growth
factor (7, 9), consistent with lack of AP2 binding or co-localiza-
tion with AP2 (6, 7). However, it was reported that in cells
treated with siRNA to down-regulate CHC17, over-expressed
CHC22 was apparently able to rescue endocytosis of transfer-
rin, suggesting potential redundant roles of the two heavy-
chain isoforms (13).
To address whether CHC22 forms coated vesicles at the
plasma membrane, we used electron microscopy to quantify
the presence of clathrin-coated structures at the plasma mem-
brane in cells treated with siRNA targeting CHC22 or CHC17
(Fig. 4).We found, as expected, that siRNA-mediated depletion
ofCHC17 caused near-complete elimination of clathrin-coated
structures at the plasma membrane compared with control
siRNA-treated cells. However, CHC22 depletion had no signif-
icant effect on the prevalence of clathrin-coated pits or vesicles
at the plasmamembrane compared with cells treated with con-
trol siRNA (Fig. 4). Together with our previous work showing
that CHC22 is not localized to the plasma membrane (6, 9),
these new data establish that endogenous CHC22 does not sup-
port formation of clathrin-coated structures at the plasma
membrane.
To address whether CHC22 can substitute for CHC17 func-
tionally in endocytosis, we used a fluorescence-activated cell
sorter (FACS) to quantitatively measure Tf uptake and directly
measure levels of expression of each clathrin. To ensure analy-
sis of true receptor-mediated endocytosis and not pinocytosis,
we exposed cells to 10 g/ml of fluorescently labeled Tf at 4 °C
for surface binding, then washed to remove excess (unbound)
Tf prior to warming the cells to 37 °C. After uptake, residual
surface Tf was stripped with acidic buffer (Fig. 5A) so that cell-
associated fluorescence represented only internalized Tf from
the pulsed exposure (“Experimental procedures”). To establish
whether CHC22 can replace CHC17 function in receptor-me-
diated Tf endocytosis, we confirmed that down-regulation of
CHC17 but not CHC22 affected Tf uptake (Fig. 5, B-D). Cells
treated to down-regulate either CHC17 or CHC22 were then
sequentially transfected to express siRNA-resistant CHC17 or
CHC22, tagged with GFP (Fig. 5, C-G, supplemental Fig. S1).
The GFP tag on both “rescue” constructs made it possible to
measure their relative expression levels (Fig. 5E), so that we
Figure 4. Clathrin-coated structures at the plasmamembrane are eliminated by CHC17 depletion but not affected by CHC22 depletion. A, represen-
tative electron micrographs illustrate closed clathrin-coated structures proximal to the plasma membrane of HeLa cells treated with control siRNA, siRNA
targeting CHC22 (siCHC22), or siRNA targeting CHC17 (siCHC17).Arrows, clathrin-coated structures; *, structures at the left enlarged at the right to show clathrin
coat. Scale bars 100 nm. B, quantification of clathrin-coated structures (open (pits) and closed) proximal to the plasmamembrane in HeLa cells treated with
siRNA as in A. Clathrin-coated structures permicrometer of plasmamembrane are reduced in siCHC17-treated cells versus control (****, p 0.0001), siCHC22-
treated cells donot differ significantly fromcontrol cells (NS, not significant atp0.05);n15 cells per condition (Student’s t test).C, immunoblot ofHeLa cells
in A and B showing efficient depletion of CHC17 and CHC22 by siRNA treatment;-Actin shown as loading control. Themigration positions ofmolecular mass
markers are indicated at the right in kilodaltons and the specificity of the detecting antibody is indicated at the left.
CHC22 biochemistry
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Figure5.Receptor-mediatedendocytosisof transferrin isnot rescuedbyCHC22overexpression in theabsenceofCHC17.A, control conditions for FACS
quantification of fluorescent Tf uptake. Basal fluorescence andmaximal surface fluorescence were determined from cells incubated with Tf-AF647 or not (No
Tf), kept on ice to block endocytosis. The efficiency of surface Tf strippingwas assessedby comparing the fluorescence of unstripped cells (No strip) to cellswith
boundTf exposed to anacidwash (Acid strip). Themean fluorescence intensity (MFI) of boundTf-A647 is shown. (One-wayANOVA, noTf versusno strip andacid
strip conditions, ****, p 0.0001, n 6–18.) B, quantification of Tf uptake in cells treated with control siRNA (siCon) or with siRNA targeting CHC17 (siCHC17)
or CHC22 (siCHC22). TheMFI of the internalized Tf-A647 (after surface stripping) is shown. (One-way ANOVA, siCon versus siCHC17 and siCHC22 conditions, **,
p  0.01, n  6.) C, representative immunoblots showing endogenous CHC17 and CHC22 and expression of the GFP-tagged CHC17 and CHC22 rescue
constructs in HeLa cells transfected with siCon or siCHC17, used for experiments in B and E-G. For all blots, themigration positions of molecular mass markers
are indicated at the right in kilodaltons (kDa) and the specificity of the blotting antibody is shown at the left. Note that the TD.1 antibody used to detect CHC17
doesnotdetectGFP-CHC17due toepitopemaskingby the tag. The faintbandof the sizeof theendogenousCHC17 that is visible for the siCHC17GFP-CHC17
condition represents a cleavage product missing the GFP. The double band detected by the anti-CHC22 antibody represents full-length transfected GFP-
CHC22anda cleavageproductmissing theGFPplus endogenousCHC22.D,quantificationof CHC17 immunoblot signals from thedepletionexperimentswere
analyzed inBandE-G (Student’s t test, siCon versus siCHC17 (noDNA), *,p0.05,n3), normalized toactin immunoblot signals for each sample.E,FACS-based
quantification of GFP-CHC17 and GFP-CHC22 expression in HeLa cells after treatment with siCHC17 or siCon. The GFP-positive population of cells was divided
in three groups with low, medium, and high MFI of the transfected GFP-CHC and for each group, the MFI for fluorescent Tf-AF647 was normalized to the
Tf-AF647MFI of the siCon, no DNA condition for panels (E-G; one-way ANOVA, control (siCon, no DNA) versus all siCHC17 conditions, ****, p 0.0001; ***, p
0.001, n 6). F, Tf-AF647 uptakemeasured by FACS for cells in C-G. Results were normalized to control (siCon, no DNA) and expressed as percent internalized
Tf (one-way ANOVA, siCon versus all siCHC17 conditions, ****, p 0.0001; *, p 0.05, n 6).G, surface-bound Tf-AF647 prior to uptakemeasured by FACS for
assays in B-G (one-way ANOVA, control (siCon, no DNA) versus all siCHC17 conditions, not statistically significant, p 0.05).
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could assess whether CHC22 expressed at equivalent (or
higher) levels to CHC17 can rescue endocytosis as effectively.
We observed that in the absence of CHC17, transfection of
CHC22 did not rescue Tf uptake in this assay (Fig. 5F), even
when expressed at a higher level than that effective for rescue by
CHC17 (Fig. 5E). Starting levels of surface-bound Tf were sim-
ilar for CHC17-depleted cells transfected with either rescue
construct (Fig. 5G). Transfection ofHeLa cells thatwere treated
with control siRNA or with siRNA targeting CHC22 con-
firmed that internalization was not reduced by these treat-
ments and showed increased Tf uptake when GFP-CHC17
was transfected but not when GFP-CHC22 was transfected
(supplemental Fig. S1).
Taken together, the electron microscopy analysis of coated
pit formation and the Tf uptake assays presented here are con-
sistent with our previous studies, and strongly support the con-
clusion that CHC22 does not participate in receptor-mediated
endocytosis at the plasma membrane.
Discussion
In this study, we examined the morphology and biochemical
properties of CHC22 clathrin, which we have previously shown
is involved in regulation of GLUT4 membrane traffic in
humans (7). We show for the first time that CHC22 forms a
latticed coat on CCVs that are distinct from CHC17-coated
vesicles. We also extend our initial biochemical observations
that the C-terminal third of CHC22 forms a trimer (6) to show
that the nearly full-length CHC22x9, and by inference full-
length CHC22, has a triskelion shape similar to that of CHC17.
Notably, we find that the CHC22 lattice is stable under alkalin-
izing conditions that disassembleCHC17 and that its uncoating
properties differ from those of CHC17. Specifically, the uncoat-
ing ATPase complex of Hsc70 and auxilin that acts to remove
CHC17 from membranes does not effectively uncoat CHC22
under the same conditions, suggesting that CHC22 is uncoated
less efficiently in cells or uncoated by an alternativemechanism.
Finally, we show that CHC22 does not function in coat forma-
tion at the plasma membrane or receptor-mediated endocyto-
sis of transferrin and that the “internal” adaptor GGA2 plays a
role in preferential recruitment of CHC22 to membranes over
CHC17. Together, our data indicate that different biochemical
properties underlie the different cellular functions of the two
vertebrate CHCs.
Human GLUT4 trafficking epitomizes the different cellular
functions of CHC22 andCHC17. In humans, 70% of post-pran-
dial blood glucose is cleared by import into skeletal muscle and
fat using the GLUT4 transporter that is released from its intra-
cellular storage compartment in response to insulin (27, 28).
Our previous work supports a role for CHC22 in targeting
GLUT4 to this insulin-responsive compartment, whereas
CHC17 is known to control a different part of the GLUT4 traf-
ficking pathway by mediating endocytosis of GLUT4 to termi-
nate insulin-stimulated glucose uptake (7, 29). In muscle from
insulin-resistant T2D patients, GLUT4 trafficking is perturbed
such that GLUT4 is not released to the cell surface in response
to insulin. Instead, GLUT4 intracellular storage compartments
become over-loaded with GLUT4. CHC22 clathrin accumu-
lates at the abnormal GLUT4 compartments, whereas CHC17
localization seems unaffected (7). We identify GGA2 as a pref-
erential CHC22 adaptor, andGGA2 has been previously shown
to mediate trafficking of GLUT4 to the same intracellular
GLUT4 storage compartment where CHC22 accumulates (30).
Furthermore, we demonstrate here that CHC22 lattices are
resistant to cellular and biochemical uncoating conditions that
disassemble CHC17, indicating that CHC22 coats are appar-
entlymore stable and could be pathogenic in excess. Indeed, we
showed previously that expression of CHC22 inmouse muscle,
where it is not normally expressed, excessively traps GLUT4 in
intracellular compartments leading to elevated blood glucose
(7). Together these observations lead us to speculate that
enhancedCHC22 accumulation at the aberrantGLUT4 storage
compartment that results from insulin resistance might con-
tribute to and exacerbate GLUT4 retention. It is notable that
separate roles for CHC22 and CHC17 were also observed in a
cell line model of transient CHC22 expression during neuronal
development (8). Thus, distinct roles of these clathrins have
potential significance for additional physiological pathways.
The findings reported here further support segregated intra-
cellular functions of CHC22 and CHC17 clathrin and resolve
debates about their functional redundancy (13, 16). We dem-
onstrate by electron microscopy that CHC22 does not form
endocytic structures at the plasmamembrane, when present at
its normal levels of expression, even when CHC17 is down-
regulated. Furthermore, consistent with lack of CHC22 co-im-
munoprecipitation with the AP2 adaptor (6, 7), we show that
when CHC17 is depleted from cells to inhibit receptor-medi-
ated endocytosis of Tf, expression of CHC22 does not rescue
CHC17 function.We designed this latter experiment to specif-
ically test receptor-mediated endocytosis because previous
experiments reporting the ability of CHC22 to replace depleted
CHC17 in transferrin uptake (8, 13) used a 5- or 10-fold higher
concentration of transferrin without washing out excess prior
to uptake or stripping residual surface-bound Tf after uptake.
In these previous studies, internalization was assessed by con-
focal microscopy and receptor-mediated endocytosis would
have been accompanied by pinocytosis of unbound Tf. In the
present study, we used quantitative FACS, non-saturating con-
centrations of transferrin, and washed away excess before
initiating internalization and residual surface bound Tf was
removed, thus measuring only internalized Tf. In this assay,
CHC22 did not restore Tf uptake that was inhibited by deple-
tion of CHC17, even though CHC22 expression was higher
than levels of CHC17 that rescued Tf endocytosis. Here we
further support the non-redundant functions of the two clath-
rins by our observation that CHC22 and CHC17 form separate
CCVs in cells. We also did not observe decreased CHC22 upon
CHC17 depletion (Figs. 4C and 5C), as suggested by Borner et
al. (16). Using siRNA targeting the separate isoforms we often
see the opposite effect, that CHC22 levels tend to increase upon
CHC17 depletion (7, 9) (although no significant increase was
observed in the experiments shown here). We have shown that
whereas CHC22 does not co-immunoprecipitate with AP2, it
does associate with some adaptors that are also bound by
CHC17, including AP1 and GGA2 (6, 7). If CHC17 is depleted,
sites on these adaptors would become available for CHC22
binding, possibly explaining increased stability of CHC22
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through increased membrane association upon CHC17 loss.
Here we identify GGA2 as a shared adaptor that seems to pref-
erentially recruit CHC22 to intracellular membranes. Because
this preference is not dramatic, we propose that there are addi-
tional adaptors unique to CHC22 recruitment, which would be
required to increase local CHC22 concentration such that it
could compete with CHC17 for shared adaptor interactions.
In conclusion, we find that although CHC22 is similar to
CHC17 inmorphology, the biochemical characteristics of these
two clathrin heavy chains with 85% sequence identity are quite
different. Their uncoating and membrane recruitment are dif-
ferentially regulated, and we propose that elucidation of these
mechanisms could provide insight into the pathogenesis and
treatment of insulin resistance leading to T2D. Furthermore,
identification of CHC22’s triskelion shape and its ability to
form stable lattices set the stage for further structural and bio-
chemical understanding of CHC22 regulation and its role in
human glucose homeostasis (7), as well as in pathways of neu-
ronal development (8).
Experimental procedures
Cell culture
HeLa cells (Subtype 229) were grown in DMEMhigh glucose
supplemented with 10% fetal bovine serum (FBS), 50 units/ml
of penicillin, and 50 g/ml of streptomycin. HeLa cells
stably expressing a doxycycline-inducible construct, pJM601-
CHC22x9 (HeLa-CHC22x9-TO cells) (6) were supple-
mented with 50 g/ml of G418 and grown in media supple-
mented with tetracycline-free FBS. Expression of CHC22x9
was induced in HeLa-CHC22x9-TO cells by adding 1 g/ml
of doxycycline (or as indicated), and cells were cultured 24 h
before harvest. Stable HeLa cell clones expressing CD8 con-
structs (from Matthew Seaman, Cambridge University) were
produced and cultured as described (26).
siRNA-mediated depletion of CHC isoforms
HeLa cells were transfected with siRNAs targeting CHC17
(40 nM), CHC22 (20 nM), or All-Star Negative control siRNA
(40 nM) (Qiagen) (31) using JetPrime (Polyplus) transfection
reagent according to the manufacturers’ instructions. Cells
were analyzed 72 or 96 h after transfection was initiated.
Preparation ofmembrane and CCV fractions
CCVpreparationwas similar toHirst et al. (17). HeLa cells or
HeLa-CHC22x9-TO cells exposed to 1 g/ml of doxycycline
were grown on four 500-cm2 dishes. Cells were rinsed with
ice-cold PBS followed by ice-cold Buffer A (0.1 M MES, pH 6.5,
0.2mMEGTA, 0.5mMMgCl2, 0.02%NaN3, 0.2mMPMSF), then
scraped in 4ml of BufferA per dish.Homogenization by Potter-
Elvehjem homogenizer (15 strokes) or by sonication was fol-
lowed by centrifugation (2,000  g for 30 min), and superna-
tants were treated with 10 g/ml of RNase A (30 min, 4 °C).
Membraneswere thenpelleted (109,000 g, 30min) and resus-
pended in 300l of Buffer A. To separate CCVs from themem-
brane fraction, the suspension was mixed with equal volumes
(300 l) of 12.5% Ficoll and 12.5% sucrose in Buffer A and cen-
trifuged (17,400 g, 30min). The supernatant was dilutedwith
4 volumes of Buffer A (2.4 ml), and CCVs were pelleted
(109,000  g, 30 min). Pellets were resuspended in 100 l of
Buffer A.
Isolation of CHC isoforms for imaging
To purify CHC22x9, CCV pellets isolated from HeLa-
CHC22x9-TO cells suspended in HEPES buffer (10 mM
HEPES-NaOH, pH 6.5, 0.2 mM EGTA, 0.02% NaN3), then cen-
trifuged (100,000 g, 30min). The resulting pellet was stripped
gradually of CHC17 by sequential exposure to HEPES buffer
with increasing pH (10 mMHEPES-NaOH, pH 7.0, 7.5, 8.0, 8.5,
0.2 mM EGTA, 0.02% NaN3), spinning out the pellet after each
extraction. The final pellet was resuspended in high Tris buffer
(50% Buffer A and 50% 1 M Tris-HCl, 2 mM EDTA, 0.4 mM
PMSF, pH 7.0), then centrifuged to yield a supernatant contain-
ing pure CHC22x9, which was imaged. To produce a similar
preparation of purified CHC17, CCVs were isolated from
untransfected HeLa cells and washed in HEPES buffer, pH 6.5,
then CHC17 was stripped from the resulting pellet by extrac-
tion in HEPES buffer, pH 7.0. Deep-etch replicas of each sepa-
rated CHCwere prepared by adsorbing proteins onmica flakes
and then quick-freezing, freeze-fracturing, deep-etching, and
platinum-replicating (32), in a fee-for-service arrangement
at the Washington University Center for Cellular Imaging, St.
Louis, MO.
Separation of CHC isoforms by SDS-PAGE
CHC isoforms were separated by electrophoresis in contin-
uous TAE-buffered SDS-PAGE (18). TAE gels were prepared
with 6.3% acrylamide, 0.17% bisacrylamide, 0.1 M Tris-HCl, 0.2
M sodium acetate, 0.02 M EDTA, 0.1% SDS, pH 7.4, and polym-
erized with 0.075% tetramethylethylenediamine and 0.75%
ammonium persulfate. Samples in standard Laemmli SDS
buffer were electrophoresed 3 h in 0.1 MTris-HCl, 0.2 M sodium
acetate, 0.02 M EDTA, 0.1% SDS, pH 7.4, at 100 mA (	70 V), at
22 °C.
Immunoblotting
Protein samples were separated by SDS-PAGE (10% acryl-
amide or TAE, 6.3% acrylamide) and transferred to nitrocellu-
lose. TAE gels were incubated in transfer buffer (50mMTris, 39
mM glycine, 0.037% SDS, 20% methanol pH 8.3) for 30 min at
22 °C prior to transfer. Membranes were labeled with primary
antibodies (1–5 g/ml) as follows: anti-CHC17 (TD.1, self-
raised mouse monoclonal against CHC17 terminal domain)
(33) or anti-CHC22 (SHL-KS, affinity purified self-raised rabbit
polyclonal against CHC22 C terminus cross-absorbed against
the CHC17 C terminus) (6, 34). For Fig. 1A, TD.1 antibody at
0.27g/mlwasmixedwith SHL-KS to achieve equivalent label-
ing of both CHC isoforms. Horseradish peroxidase (HRP)-con-
jugated secondary antibodies were detected using ECLTM re-
agent (Amersham Biosciences). Quantification was performed
using ImageJ (NIH).
Uncoating assays
Uncoating experiments weremodified from a published pro-
tocol (35). To prepare CCVs, HeLa cells (confluent 500 cm2
dish) were rinsed three times in PBS (4 °C), removed by scrap-
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ing, resuspended in 900 l of uncoating buffer (40 mM HEPES,
pH 7.4, 75 mM KCl, 4.5 mM MgCl2, 1.5 mM CaCl2) supple-
mentedwith protease inhibitors (2g/ml of aprotinin, 1mg/ml
of leupeptin, 0.005% PMSF), and homogenized by a Potter-
Elvehjem homogenizer (5 strokes). Homogenates were centri-
fuged (1000  g, 15 min), then the post-nuclear supernatants
were centrifuged (10 min, 100,000  g). To generate a crude
CCV fraction, the pellet was exposed to detergent to remove
uncoated membranes, then rinsed to remove excess detergent,
resuspended in 900 l of uncoating buffer (room temperature,
15 min to release free triskelia), then centrifuged (10 min,
100,000 g) and resuspended in 900l of uncoating buffer (50
g/ml). The uncoating reaction was allowed to reach steady-
state for 10 min, 37 °C with full-length rat Hsc70 (1.3 M)
recombinantly produced in Sf9 cells, GST-auxilin(401–910)
(bovine) (0.13M) recombinantly produced in BL21-DE bacte-
ria, and ATP (0.5 mM) (36), then samples were centrifuged (30
min, 100,000  g) to analyze pellet and supernatant by immu-
noblotting for CHCs.
Immunogold labeling of HeLa CCVs
CCVs prepared from HeLa cells (Buffer A) were adsorbed to
freshly glow-discharged formvar/carbon-coated copper mesh
EM grids for 2 min. Samples were washed by transferring EM
grids between 20-l drops of buffer A to buffer G (25 mM
HEPES, 125 mM potassium acetate, 5 mM magnesium acetate,
pH 7.2), then fixed on 20 l of 0.1% glutaraldehyde in buffer G
for 15 min. Samples were blocked by transfer over buffer G,
then PBS, then PBS with 0.15 M glycine, pH 7.2, for 5 min, and
PBSwith 1% (m/v) fish gelatin for 30min. Sampleswere double-
labeled withmousemonoclonal anti-CLC (decorating CHC17)
(CON.1, 4 g/ml) (33) and anti-CHC22 (SHL-KS, diluted
1:200) in PBS with 1% fish gelatin for 1 h, then washed by suc-
cessive transfer over six 20-l drops of PBSwith 1% fish gelatin.
To minimize background from secondary antibodies (5/10 nm
gold-labeled goat anti-mouse/rabbit antibodies diluted 1:30 in
1% fish gelatin in PBS), diluted antibodieswere pre-adsorbed on
unlabeled, fixed HeLa CCVs on EM grids for 1 h, then 20 l
were used to detect primary antibody labeling for 1 h. After
labeling, samples were washed three times in PBS with 1% fish
gelatin, twice in PBS, then fixed in 2.5% glutaraldehyde in PBS
(10min), washed twicewith PBS and distilledwater and stained
with (2% (m/v) uranyl acetate/water). All steps were at room
temperature (22 °C).
Statistical analysis of immunogold-labeled HeLa CCVs
Although only 6.9% of multi-labeled CCVs contained labels
for CHC17 and CHC22, we asked if this proportion was signif-
icantly different from what we would expect if all CCV coats
contained both heavy chains. This analysis is complicated by
several factors, including: 1) the actual abundance of each pro-
tein in cells, CHC17 is	10 times more abundant than CHC22
(9); 2) the efficiency of each primary and secondary antibody
used for staining, likely to be different for each epitope and
difficult to estimate; and 3) the proportion of each CHC that is
in CCVs as opposed to free in the cytosol, again unknown,
although our previous data and those presented here indicate
that CHC22 is more likely to be found on membranes than
CHC17. Given these unknowns, we used the CCVs with only
one label (by definition either CHC17 orCHC22) to empirically
determine the likelihood of a given label being CHC17 or
CHC22. This analysis showed that a given label had a 62.6%
chance of being CHC17 and a 37.4% chance of being CHC22.
We used these probabilities to calculate the expected number
of dual-labeled CCVs. As this is simplest in the case of CCVs
labeled with exactly two gold particles we limited our statistical
analysis to this case, which included 190 analyzed CCVs. We
calculated expected numbers to be: 1) both labels are CHC22
14 or 26%CCVs; 2) oneCHC17 label and oneCHC22 label 47
or 89%CCVs; 3) both labels areCHC17 40 or 75%CCVs; if all
CCVs are composed of CHC17 and CHC22 at a 10:1 ratio. We
then conducted a 2 test to determine whether our observed 11
dual-labeled CCVswas significantly lower than the expected 89
dual-labeledCCVs. This was highly significant (p 0.0001, n
190 CCVs with two labels, df 1), suggesting that CHC17 and
CHC22 form separate populations of CCVs.
Embedding and ultra-thin sectioning of HeLa cells
For ultra-thin sectioning, siRNA-treated HeLa cells washed
twice (5 mM EDTA, 4.5 g/liter of glucose in PBS, pH 7.3, 37 °C)
were resuspended (same buffer, 10 min) and an aliquot was
removed to assess expression ofCHC isoforms by immunoblot-
ting. Cells (pelleted 300 g, 6 min, 4 °C) were fixed (3% glutar-
aldehyde in 0.1 M cacodylate, pH 7.2), then processed for
embedding in Epon and stained as described (37). For quantifi-
cation of clathrin-coated structures, images of ultra-thin sec-
tions of embedded cells were analyzed using NIH ImageJ by
observers blind to condition.
FACS-based assay of Tf uptake
HeLa cells were treated with siRNA targeting each CHC or
All-Star Negative control siRNA (20 nM) (Qiagen) for 72 h.
During the last 24 h of siRNA transfection, cDNA encoding
green fluorescent protein (GFP)-tagged CHC17 or CHC22 was
transfected and experiments were started the next day. For
transferrin uptake assays, cells were starved of FBS for 2 h in
uptake media (DMEM 0.1% BSA) then incubated with Alexa
Fluor 647-coupled transferrin (Tf-AF647ThermoFisher Scien-
tific), 10 g/ml in ice-cold uptake media; for 10 min on ice.
Unbound Tf-AF647 was removed by 3 successive washes (ice-
cold PBS). Uptake was then initiated by adding warm uptake
media to the cells and endocytosis was allowed to proceed for
10 min at 37 °C. After uptake, cells were placed back on ice and
residual surface-bound Tf-AF647 was removed by 3 successive
washes (ice-cold PBS), followed by two acid washes (0.15 M
glycine buffer, pH 3) to strip any remaining surface Tf-AF647,
and finally a further 3 successive washes (ice-cold PBS). The
cells were then fixed in 4% paraformaldehyde for 15 min on ice
and then 15 min at room temperature. The cells were then
gently lifted using a cell scraper, pelleted (800  g, 8 min), and
re-suspended inPBS, 2%BSA for subsequent flowcytometer anal-
ysis (LSRII, BD Biosciences) using the DIVA software (BD Biosci-
ences) to simultaneously measure levels of cell-associated
Tf-AF647 and levels of transfected CHC (GFP). Cells expressing
GFP constructs were divided into three groups based on lev-
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els of expression (low, medium, and high) each representing
one-third of the GFP fluorescence intensity spectrum.
To develop and validate the FACS-based Tf-uptake assay,
three control conditions were evaluated for each assay: (i) cells
were mock-treated without Tf-AF647 to determine the non-
specific fluorescent background; (ii) cells were fixed with para-
formaldehyde after removal of excess Tf-AF647 to determine
the amount of surface transferrin bound prior to uptake; (iii)
cellswere left on ice after bindingTf and then exposed to an acidic
strip to test the efficacy of surface-bound Tf stripping. As remov-
ing surface Tf-AF647 with the acid wash was key for ensuring the
specificity the assay,weverified formultiple repeats that condition
(ii) was statistically different from conditions (i) and (iii) before
proceeding with further assays (Fig. 5A) (one-way ANOVA, i ver-
sus ii,p0.0001; ii versus iii,p0.0001; i versus iii,NS).Cellswere
also immunoblotted to confirm CHC17 (Fig. 5, C and D) or
CHC22 (A and B) depletion for each assay.
Flow cytometry data were analyzed using FlowJo (Treestar).
Immunoblot samples were quantified (ImageJ, NIH) and nor-
malized to their respective actin loading control. For each assay,
FACS results were normalized to samples treated with control
siRNA (siCon) with no CHC-expressing DNA, as 100% uptake.
Results from six assays were pooled to create the graphs
reported in Fig. 5. CHC22 expression, CHC17 expression, sur-
face-bound Tf, and Tf-uptake were each analyzed by one-way
ANOVA (GraphPad Prism) to determine the effect of CHC17
and CHC22 levels on Tf uptake.
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